WoundSource Page Designs_White Papers small

Management of Biofilm: The Efficacy of Controlled Release Iodine

Management of Biofilm The Efficacy of Controlled Release Iodine
 
By submitting your information through this form, you confirm that you agree to WoundSource's Privacy Policy, as well as sharing your information with any partners for marketing purposes. You can opt out at any time.
 

Chronic wounds affect approximately 6.5 million patients in the United States, and the number is increasing. Almost all chronic wounds contain biofilm, which is resistant to most antibiotics and many current antibacterial therapies. In the search for effective products to reduce biofilm, iodine dressings have outperformed other antibacterial dressings, including silver-based products, in several in vitro studies.

This illustrated and extensively referenced white paper, sponsored by Medline Industries, makers of IoPlex, discusses the value of iodine in biofilm management and describes the research demonstrating its effectiveness. IoPlex, a controlled-release iodine foam dressing, has potent in vitro activity against biofilms caused by several common pathogens. Although the clinical implications of these findings have yet to be determined, these results suggest that IoPlex may be effective for managing biofilm in wounds.

For wound care professionals, biofilm management presents an ongoing challenge. This white paper reports encouraging findings with a controlled-release iodine dressing in the quest to reduce biofilms in chronic wounds.

This white paper covers the following topics:

Epidemiology and costs of chronic wounds
Biofilm as an impediment to wound healing
Historical versus contemporary iodine therapy
In vitro studies comparing antibacterial wound dressings
IoPlex as a promising dressing for biofilm reduction

Sponsored by Medline Industries, Inc.

Chronic wounds affect approximately 6.5 million patients in the United States, and the number is increasing. Almost all chronic wounds contain biofilm, which is resistant to most antibiotics and many current antibacterial therapies. In the search for effective products to reduce biofilm, iodine dressings have outperformed other antibacterial dressings, including silver-based products, in several in vitro studies.

This illustrated and extensively referenced white paper, sponsored by Medline Industries, makers of IoPlex, discusses the value of iodine in biofilm management and describes the research demonstrating its effectiveness. IoPlex, a controlled-release iodine foam dressing, has potent in vitro activity against biofilms caused by several common pathogens. Although the clinical implications of these findings have yet to be determined, these results suggest that IoPlex may be effective for managing biofilm in wounds.

For wound care professionals, biofilm management presents an ongoing challenge. This white paper reports encouraging findings with a controlled-release iodine dressing in the quest to reduce biofilms in chronic wounds.

This white paper covers the following topics:

Epidemiology and costs of chronic wounds
Biofilm as an impediment to wound healing
Historical versus contemporary iodine therapy
Antibacterial effectiveness of iodine dressings
IoPlex as a promising dressing for biofilm reduction

Sponsored by Medline Industries, Inc.

WoundSource
The World’s Definitive Source for Wound Care & Product Information